Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01535937 · ClinicalTrials.gov registry record · Phase 1
The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01535937 is a Phase 1 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 55 participants.
The verdict
NCT01535937, a Phase 1 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This project will evaluate the effect of a single sub-anesthetic dose of ketamine on the time to first cocaine use and abstinence rates in 60 treatment-seeking cocaine-dependent individuals receiving mindfulness-based relapse prevention (MBRP) therapy, using a 5 week combined laboratory-inpatient and outpatient double-blind, randomized, controlled trial.
Interventions
- DRUG Ketamine
- DRUG Midazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2012-02 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01535937
The ClinicalTrials.gov registry entry for NCT01535937 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT01535937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01535937 about?
NCT01535937 is a clinical study titled "The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence". This project will evaluate the effect of a single sub-anesthetic dose of ketamine on the time to first cocaine use and abstinence rates in 60 treatment-seeking cocaine-dependent individuals receiving mindfulness-based relapse prevention (MBRP) therapy, using a 5 week combined laboratory-inpatient an...
What is the current status of trial NCT01535937?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2012-02. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01535937?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT01535937?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.